Is AFib Common After Stent Placement?

Atrial fibrillation does occur after coronary stent placement, with new-onset rates reported in roughly 3 to 8 percent of patients depending on the clinical setting and which artery is treated. That range makes it uncommon for any individual patient but frequent enough to be a recognized clinical concern, especially because managing blood thinners for a stent and for AFib at the same time creates a genuine treatment dilemma. The overlap between these two conditions runs deeper than most patients realize, and the way cardiologists handle it has changed substantially in recent years.

How Often Does AFib Appear After Stenting?

The numbers depend on context. In patients undergoing stent placement for a heart attack caused by a complete blockage, about 3 percent develop atrial fibrillation shortly after the procedure. That figure comes from a study of more than 1,700 patients who had primary angioplasty for the most serious type of heart attack, an ST-elevation myocardial infarction.¹ When the stent specifically goes into the right coronary artery, the rate climbs higher. A study of 765 patients found that about 7.5 percent developed new-onset AFib during follow-up, with the risk concentrated in those who had stents placed in the near or far segments of that particular artery.²

Separately, when researchers look at how many patients already carry an AFib diagnosis at the time they arrive for a stent, that prevalence sits around 7 percent. In a large registry study, 711 out of roughly 10,000 patients receiving drug-eluting stents had a known AFib diagnosis before the procedure even began.³ That distinction matters: the question is not just whether AFib shows up after a stent, but also how often these two conditions already coexist when a patient walks through the door. Either way, cardiologists encounter the combination regularly.

Why Coronary Artery Disease and AFib Travel Together

The conditions are not coincidental neighbors. Coronary artery disease and atrial fibrillation share a set of underlying risk factors that make people vulnerable to both. High blood pressure, diabetes, obesity, sleep apnea, and smoking all raise the odds of blocked arteries and of irregular heart rhythms.⁴ Chronic inflammation plays a role in both diseases too, damaging artery walls while simultaneously remodeling the electrical tissue in the upper chambers of the heart.

Beyond shared risk factors, the stent procedure itself can trigger AFib. Any heart attack causes ischemia, meaning heart tissue is temporarily starved of oxygen, and ischemia can destabilize the electrical signals in the atria. Patients who were older, who had more severe heart failure on arrival, or whose artery was completely blocked before the procedure were more likely to develop AFib afterward.¹ Unsuccessful reperfusion, meaning the blood flow was not fully restored, also raised the risk. In other words, the sicker you were going into the procedure, the more likely you were to develop AFib coming out of it.

Electrolyte shifts during and around the procedure may add fuel as well. Low sodium levels change the shape of the electrical impulse in heart cells in ways that make atrial fibrillation more sustainable once it starts. Low potassium alters how fast electrical signals travel through the atrial tissue, making it easier to trigger arrhythmias, especially when there is pre-existing scarring in the heart.⁵ Patients undergoing catheterization can experience fluid shifts and electrolyte changes from contrast dye, IV fluids, and fasting, all of which might nudge a vulnerable heart toward fibrillation.

Which Artery and Which Stent Type Influence the Risk

Not all stent locations carry equal AFib risk. The right coronary artery stands out because it typically supplies blood to the sinus node and the AV node, the two clusters of cells that set the heart’s rhythm. When blood flow in that artery is disrupted, even temporarily, the electrical command centers can misfire. The study that found a 7.5 percent new-onset AFib rate noted that stenting in the right coronary artery was independently associated with post-procedural complications and heart failure.²

The type of stent matters for a different reason. Newer-generation drug-eluting stents appear to lower the risk of developing new AFib compared with older bare-metal stents. In a large analysis of patients with stable coronary artery disease, newer drug-eluting stents were linked to about a 20 percent reduction in the risk of new-onset AFib at one year.⁶ That benefit held even in patients who already had higher stroke-risk profiles. The mechanism is not entirely clear, but drug-eluting stents cause less vessel inflammation and restenosis, and lower levels of vascular inflammation could translate to less electrical irritation in the atria. When comparing outcomes between stent types in patients who already had AFib, older age and placement during a heart attack were the strongest independent predictors of major adverse cardiac events, regardless of stent type.⁷

The Blood Thinner Balancing Act

Here is where AFib after stenting gets genuinely complicated for patients and doctors alike. A newly placed stent needs two antiplatelet drugs to prevent a clot from forming inside it. AFib needs an anticoagulant to prevent stroke-causing clots from forming in the heart’s upper chambers. Combining all three creates what cardiologists call “triple therapy,” and the predictable problem is bleeding. You are thinning the blood from three different angles at once.

The evidence on this has become fairly clear. Multiple large trials have now compared dual therapy, which drops aspirin and keeps an anticoagulant plus a single antiplatelet, against the traditional triple approach. A systematic review pooling data from major randomized trials found that dual therapy reduced major bleeding with high confidence.⁸ A separate systematic review confirmed the bleeding reduction was substantial: for every 16 patients put on triple therapy instead of double therapy, one extra patient experienced a significant bleed. Intracranial hemorrhages, the most feared complication, were also roughly cut in half with the dual approach.⁹

A key trial in shaping this shift tested the newer anticoagulant apixaban against warfarin in patients with AFib who had just had a stent placed or who were being treated for a heart attack, in combination with or without aspirin.¹⁰ The results reinforced two things: newer anticoagulants were preferable to warfarin in this setting, and dropping aspirin early reduced bleeding without a clear increase in stent clots or heart attacks.

How Quickly the Guidelines Moved

The speed at which clinical practice changed is striking. In a Japanese survey of cardiologists, 85 percent still preferred warfarin for these patients in 2014, even though newer oral anticoagulants were already available. By 2016, more than three-quarters had switched to those newer drugs, and within a few more years the shift was essentially universal.¹¹

Current guidelines now recommend keeping triple therapy as short as possible. For most patients, that means just one week of all three drugs after stent placement, then switching to dual therapy with an anticoagulant and a single antiplatelet. Patients at particularly high risk for stent clots may stay on triple therapy for up to a month, but rarely longer.¹² This is a major departure from earlier practice, when many patients were kept on triple therapy for six months or even a year. The change reflects accumulating evidence that the bleeding risks of prolonged triple therapy outweigh whatever marginal clot-prevention benefit it might offer. For patients worried about the pill burden and the bruising and bleeding nuisances that come with aggressive blood thinning, the shorter course is a meaningful quality-of-life improvement.

Long-Term Outlook When Both Conditions Coexist

Having AFib on top of coronary artery disease is not a benign combination. Over a mean follow-up of nearly five years, patients who had both AFib and coronary stenting faced roughly double the risk of death compared with stent patients who did not have AFib. That two-fold increase applied equally whether the stent was placed electively for stable disease or urgently for a heart attack.¹³

Stroke risk is another concern. A systematic review of AFib occurring during heart attacks found persuasive evidence that AFib raises the risk of stroke not just during the hospital stay but long after discharge. Even patients whose AFib was transient and had converted back to a normal rhythm by the time they left the hospital still carried a higher stroke risk during subsequent follow-up.¹⁴ That finding is important because patients and sometimes doctors assume that if the AFib goes away on its own, it was a one-time event that can be ignored. The data suggest otherwise.

Sex Differences in Outcomes

The combination of AFib and coronary stenting does not affect men and women identically. In a pooled analysis of over 1,400 Japanese patients with both conditions, women had a noticeably higher three-year death rate at first glance, around 27 percent versus 17 percent for men. After adjusting for the fact that women in the study were older and had more comorbidities, the mortality difference was no longer statistically meaningful. However, major bleeding remained significantly more common in women even after adjustment, with roughly a 47 percent higher adjusted risk.¹⁵

Age modifies the picture. In a Chinese study of patients under 65, women with AFib and coronary stents had more than double the mortality risk compared with men in the same age range, and that gap persisted after accounting for other health differences. Men in the same cohort were significantly more likely to undergo repeat procedures to reopen narrowed arteries, possibly because higher rates of smoking in men caused more aggressive disease that prompted intervention, while women’s disease may have been undertreated.¹⁶ These findings point to the possibility that younger women with both conditions represent a particularly vulnerable group that may benefit from closer follow-up and more aggressive management than they currently receive.

Catheter Ablation as a Treatment Option

For patients with persistent or bothersome AFib who also have coronary stents, catheter ablation, a procedure that destroys the tiny patches of heart tissue triggering the irregular rhythm, appears to offer substantial benefit over medications alone. In a study with a follow-up period averaging about five years, patients who underwent ablation had dramatically better outcomes than those managed with drugs. All-cause mortality was about 1 percent in the ablation group versus more than 8 percent in the medication group. Rates of stroke, hospitalization for a heart attack, and overall major adverse events were all significantly lower after ablation.¹⁷

Multivariate analysis in that study found that not receiving ablation was independently associated with a more than three-fold increase in major adverse events. These are observational data, so some of the difference likely reflects the fact that healthier patients were more likely to be offered ablation in the first place. Still, the size of the gap is hard to explain away entirely by selection bias. For patients who continue to have AFib symptoms after stenting and who are reasonable candidates for the procedure, ablation is worth a serious conversation with an electrophysiologist. It does not eliminate the need for blood thinners immediately, since stroke risk must still be managed during and after the ablation recovery period, but successful ablation can simplify the long-term medication picture and improve how patients feel day to day.

When AFib Shows Up Briefly and Disappears

One of the trickier scenarios is transient AFib, an episode that appears during or shortly after the stent procedure and then resolves on its own within hours or days. Patients often assume this is a one-off electrical hiccup caused by the stress of the procedure, nothing to worry about once the rhythm returns to normal. As noted earlier, the evidence does not support that reassuring interpretation. Even brief, self-terminating AFib during a heart attack is linked to a higher long-term stroke risk.¹⁴

This matters practically because decisions about anticoagulation sometimes hinge on whether AFib is considered “real” or just a transient stress response. The question of whether a patient who had one brief episode of post-procedural AFib needs ongoing anticoagulation does not have a universally agreed-upon answer, and it involves weighing the individual’s stroke risk profile against their bleeding risk. What the data make clear is that dismissing transient post-stent AFib as irrelevant is premature. These patients deserve follow-up monitoring, at a minimum, to see whether the arrhythmia recurs, and a candid discussion about whether the episode warrants stroke prevention therapy. The shared risk factors that brought them to the cath lab in the first place, including high blood pressure, diabetes, and obesity, are the same factors that make AFib more likely to return.⁴

1
PubMed Central. Atrial fibrillation after but not before primary angioplasty for ST-segment elevation myocardial infarction of prognostic importance
2
EP Europace. New onset atrial fibrillation after stenting of the right coronary artery in patients with ischemic disease of the heart
3
PubMed. Prevalence, Management, and Long-Term (6-Year) Outcomes of Atrial Fibrillation Among Patients Receiving Drug-Eluting Coronary Stents
4
Advances in Medical Sciences. Patients with atrial fibrillation and coronary artery disease – Double trouble
5
Communications Medicine. The effect of clinically relevant changes in extracellular electrolyte concentrations on human atrial arrhythmias
6
International Journal of Cardiology. Risk of new-onset atrial fibrillation after drug-eluting stent implantation in patients with stable coronary artery disease
7
The American Journal of Cardiology. Comparison of Frequency of Major Adverse Events in Patients With Atrial Fibrillation Receiving Bare-Metal Versus Drug-Eluting Stents in Their Coronary Arteries
8
PubMed Central. Dual Versus Triple Therapy for Atrial Fibrillation After Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis
9
PubMed Central. A systematic review of randomized trials comparing double versus triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention
10
PubMed. Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation
11
PubMed Central. Temporal Trends in Antithrombotic Therapy for Patients With Atrial With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention From 2014 to 2022 in Japan
12
PubMed Central. The role of triple antithrombotic therapy in patients with atrial fibrillation and coronary stent insertion
13
International Journal of Cardiology. Long-term mortality of patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation for acute and stable coronary artery disease
14
European Heart Journal. Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications
15
PubMed. Sex Differences in Long-Term Clinical Outcomes in Patients With Atrial Fibrillation Undergoing Coronary Stent Implantation
16
Anatol J Cardiol. Sex difference in clinical outcomes of Chinese patients with atrial fibrillation and coronary stenting according to age
17
Heart, Lung and Circulation. When Atrial Fibrillation Co-Exists with Coronary Artery Disease in Patients with Prior Coronary Intervention – Does Ablation Benefit?